Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (54)
Right arrowRequest Permissions
Right arrow Disclaimer
Citing Articles
Right arrowScopus Links
Right arrowCiting Articles via CrossRef
Google Scholar
Right arrow Articles by Morand, E. F.
Right arrow Articles by Smith, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morand, E. F.
Right arrow Articles by Smith, M. D.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 558-562
© 2002 British Society for Rheumatology

Original Papers

Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations

E. F. Morand, M. Leech, H. Weedon1, C. Metz2, R. Bucala2 and M. D. Smith1

Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne,
1 Repatriation General Hospital, Daw Park, Adelaide, South Australia, Australia and
2 Picower Institute for Medical Research, Manhasset, NY, USA

Objective. Cytokines play an important role in the pathology of rheumatoid arthritis (RA). Macrophage migration inhibitory factor (MIF) is a cytokine with a broad spectrum of actions, including induction of monocyte tumour necrosis factor {alpha} (TNF-{alpha}). Evidence of the expression and proinflammatory activity of MIF has recently been demonstrated in RA synovium and in animal models of RA. We wished to assess the relationship between MIF expression in synovium and clinical disease.

Methods. Computer-assisted analysis of the cytokine content of arthroscopically obtained biopsies of RA synovium, using paired samples from eight patients with active and inactive/treated disease, was compared with documented clinical parameters.

Results. Synovial MIF immunostaining correlated strongly with disease activity as measured by CRP concentration. Reductions in clinical disease parameters, including CRP, tender and swollen joint counts, were accompanied by significant reductions in synovial MIF. Synovial TNF-{alpha}, transforming growth factor ß (TGF-ß) and interleukin (IL) 10 also showed a significant reduction in association with reduced disease activity, while IL-1ß and IL-1 receptor agonist did not.

Conclusion. The correlation of synovial MIF with disease activity corroborates existing evidence of the role of this cytokine in RA. The demonstration that only MIF and TNF-{alpha} show significant variation in synovial cytokine content with clinical remission suggests that MIF is an important member of the cytokine hierarchy in RA.

KEY WORDS: Macrophage, Fibroblast, Glucocorticoids, Synovial, Cytokine, Macrophage migration inhibitory factor, Rheumatoid arthritis.

Correspondence to: E. F. Morand, Centre for Inflammatory Diseases, Monash Medical Centre, Locked Bag No. 29, Clayton 3168, Melbourne, Australia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
Y. Sanchez-Zamora, L. I. Terrazas, A. Vilches-Flores, E. Leal, I. Juarez, C. Whitacre, A. Kithcart, J. Pruitt, T. Sielecki, A. R. Satoskar, et al.
Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus
FASEB J, July 1, 2010; 24(7): 2583 - 2590.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
H. Ouertatani-Sakouhi, M. Liu, F. El-Turk, G. D. Cuny, M. A. Glicksman, and H. A. Lashuel
Kinetic-Based High-Throughput Screening Assay to Discover Novel Classes of Macrophage Migration Inhibitory Factor Inhibitors
J Biomol Screen, April 1, 2010; 15(4): 347 - 358.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. K. Brown, F. H. Blaikie, R. A. J. Smith, J. D. A. Tyndall, H. Lue, J. Bernhagen, C. C. Winterbourn, and M. B. Hampton
Direct Modification of the Proinflammatory Cytokine Macrophage Migration Inhibitory Factor by Dietary Isothiocyanates
J. Biol. Chem., November 20, 2009; 284(47): 32425 - 32433.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. Flaster, J. Bernhagen, T. Calandra, and R. Bucala
The Macrophage Migration Inhibitory Factor-Glucocorticoid Dyad: Regulation of Inflammation and Immunity
Mol. Endocrinol., June 1, 2007; 21(6): 1267 - 1280.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. Aeberli, M. Leech, and E. F. Morand
Macrophage migration inhibitory factor and glucocorticoid sensitivity
Rheumatology, August 1, 2006; 45(8): 937 - 943.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.